Baicalein decreases uric acid and prevents hyperuricemic nephropathy in mice

Oncotarget

Volumn 8, Issue 25, 2017, Pages 40305-40317

  Meng, Xiaolu ^a   Mao, Zhuo ^b   Li, Xin ^c   Zhong, Dandan ^a   Li, Min ^a   Jia, Yingli ^a   Wei, Jing ^b   Yang, Baoxue ^a   Zhou, Hong ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b TIANJIN UNIVERSITY   (China)

^c QINGDAO UNIVERSITY   (China)

Author keywords

Baicalein; Hyperuricemia; Nephropathy; Uric acid; Xanthine oxidoreductase

Indexed keywords

BAICALEIN; XANTHINE OXIDASE; ANTIOXIDANT; FLAVANONE DERIVATIVE; XANTHINE DEHYDROGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG PROTEIN BINDING; EPITHELIAL MESENCHYMAL TRANSITION; KIDNEY DYSFUNCTION; KIDNEY FIBROSIS; MALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; OXIDATIVE STRESS; RENAL PROTECTION; SURFACE PLASMON RESONANCE; URIC ACID NEPHROPATHY; ANIMAL; DISEASE MODEL; DRUG EFFECT; GOUT; HYPERURICEMIA; INSTITUTE FOR CANCER RESEARCH MOUSE; KIDNEY; KIDNEY DISEASE; METABOLISM; PATHOLOGY;

ANIMALS; ANTIOXIDANTS; DISEASE MODELS, ANIMAL; EPITHELIAL-MESENCHYMAL TRANSITION; FLAVANONES; GOUT; HYPERURICEMIA; KIDNEY; KIDNEY DISEASES; MALE; MICE; MICE, INBRED ICR; MOLECULAR DOCKING SIMULATION; OXIDATIVE STRESS; SURFACE PLASMON RESONANCE; XANTHINE DEHYDROGENASE;

EID: 85020965159     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.16928     Document Type: Article

References (62)

1. Tasic V, Janchevska A, Emini N, Sahpazova E, Gucev Z, Polenakovic M. Chronic kidney disease-pediatric risk factors. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2016; 37:9-13
2. Acevedo A, Benavides J, Chowdhury M, Lopez M, Pena L, Montenegro A, Lievano M, Lombo B. Hyperuricemia and Cardiovascular Disease in Patients with Hypertension. Conn Med. 2016; 80:85-90
3. Jalal DI. Hyperuricemia, the kidneys, and the spectrum of associated diseases: a narrative review. Curr Med Res Opin. 2016:1-7
4. Kawada T. Cross-sectional and longitudinal study on the association between serum uric acid and metabolic syndrome. Clin Chim Acta. 2016; 455:201
5. Shao X, Lu W, Gao F, Li D, Hu J, Li Y, Zuo Z, Jie H, Zhao Y, Cen X. Uric Acid Induces Cognitive Dysfunction through Hippocampal Inflammation in Rodents and Humans. J Neurosci. 2016; 36:10990-11005
6. Liu CW, Liao PC, Chen KC, Chiu YW, Liu YH, Ke SR, Wu YW. Relationship of serum uric acid and Killip class on mortality after acute ST-segment elevation myocardial infarction and primary percutaneous coronary intervention. Int J Cardiol. 2016; 226:26-33
7. Yasu T, Kobayashi S, Horii M, Kurokawa Y. The efficacy of febuxostat 10 mg for the prevention of hyperuricemia associated with tumor lysis syndrome (TLS) in Japanese patients with non-Hodgkin's lymphoma. Int J Clin Pharmacol Ther. 2016; 54:1009-1012
8. Kim IY, Lee DW, Lee SB. The role of uric acid in kidney fibrosis: experimental evidences for the causal relationship. 2014; 2014:638732
9. Nashar K, Fried LF. Hyperuricemia and the progression of chronic kidney disease: is uric acid a marker or an independent risk factor? Adv Chronic Kidney Dis. 2012; 19:386-391
10. Feig DI. Uric acid: a novel mediator and marker of risk in chronic kidney disease? Curr Opin Nephrol Hypertens. 2009; 18:526-530
11. Dousdampanis P, Trigka K, Musso CG, Fourtounas C. Hyperuricemia and chronic kidney disease: an enigma yet to be solved. Ren Fail. 2014; 36:1351-1359
12. Stamp L, Dalbeth N. Urate-lowering therapy for asymptomatic hyperuricaemia: A need for caution. Semin Arthritis Rheum. 2016
13. Levy G, Cheetham TC. Is It Time to Start Treating Asymptomatic Hyperuricemia? Am J Kidney Dis. 2015; 66:933-935
14. Wang H, Wei Y, Kong X, Xu D. Effects of urate-lowering therapy in hyperuricemia on slowing the progression of renal function: a meta-analysis. J Ren Nutr. 2013; 23:389-396
15. Okamoto K, Matsumoto K, Hille R, Eger BT, Pai EF, Nishino T. The crystal structure of xanthine oxidoreductase during catalysis: implications for reaction mechanism and enzyme inhibition. Proc Natl Acad Sci U S A. 2004; 101:7931-7936
16. Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF, Nishino T. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem. 2003; 278:1848-1855
17. Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016; 388:2039-2052
18. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012; 64:1431-1446
19. Lin J, Chen S, Li S, Lu M, Li Y. Efficacy and Safety of Chinese Medicinal Herbs for the Treatment of Hyperuricemia: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med. 2016; 2016:2146204
20. Tsai KL, Hung CH, Chan SH, Shih JY, Cheng YH, Tsai YJ, Lin HC, Chu PM. Baicalein protects against oxLDL-caused oxidative stress and inflammation by modulation of AMPKalpha. Oncotarget. 2016; 7:72458-72468. doi: 10.18632/oncotarget.12788
21. Gaire BP, Moon SK, Kim H. Scutellaria baicalensis in stroke management: nature's blessing in traditional Eastern medicine. Chin J Integr Med. 2014; 20:712-720
22. Li J, Ma J, Wang KS, Mi C, Wang Z, Piao LX, Xu GH, Li X, Lee JJ, Jin X. Baicalein inhibits TNF-alpha-induced NFkappaB activation and expression of NF-kappaB-regulated target gene products. Oncol Rep. 2016; 36:2771-2776
23. Liu H, Dong Y, Gao Y, Du Z, Wang Y, Cheng P, Chen A, Huang H. The Fascinating Effects of Baicalein on Cancer: A Review. Int J Mol Sci. 2016; 17
24. Wang W, Zhou PH, Xu CG, Zhou XJ, Hu W, Zhang J. Baicalein attenuates renal fibrosis by inhibiting inflammation via down-regulating NF-kappaB and MAPK signal pathways. J Mol Histol. 2015; 46:283-290
25. Wang W, Zhou PH, Xu CG, Zhou XJ, Hu W, Zhang J. Baicalein ameliorates renal interstitial fibrosis by inducing myofibroblast apoptosis in vivo and in vitro. BJU Int. 2016; 118:145-152
26. Zhao F, Fu L, Yang W, Dong Y, Yang J, Sun S, Hou Y. Cardioprotective effects of baicalein on heart failure via modulation of Ca(2+) handling proteins in vivo and in vitro. Life Sci. 2016; 145:213-223
27. Chen M, Lai L, Li X, Zhang X, He X, Liu W, Li R, Ke X, Fu C, Huang Z, Duan C. Baicalein Attenuates Neurological Deficits and Preserves Blood-Brain Barrier Integrity in a Rat Model of Intracerebral Hemorrhage. Neurochem Res. 2016; 41:3095-3102
28. Ribeiro AR, do Nascimento Valenca JD, da Silva Santos J, Boeing T, da Silva LM, de Andrade SF, Albuquerque-Junior RL, Thomazzi SM. The effects of baicalein on gastric mucosal ulcerations in mice: Protective pathways and antisecretory mechanisms. Chem Biol Interact. 2016; 260:33-41
29. Isaka Y, Takabatake Y, Takahashi A, Saitoh T, Yoshimori T. Hyperuricemia-induced inflammasome and kidney diseases. Nephrol Dial Transplant. 2016; 31:890-896
30. Nishino T, Okamoto K. Mechanistic insights into xanthine oxidoreductase from development studies of candidate drugs to treat hyperuricemia and gout. J Biol Inorg Chem. 2015; 20:195-207
31. Lin S, Zhang G, Liao Y, Pan J. Inhibition of chrysin on xanthine oxidase activity and its inhibition mechanism. Int J Biol Macromol. 2015; 81:274-282
32. Chen C, Lu JM, Yao Q. Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview. Med Sci Monit. 2016; 22:2501-2512
33. Rashidi MR, Nazemiyeh H. Inhibitory effects of flavonoids on molybdenum hydroxylases activity. Expert Opin Drug Metab Toxicol. 2010; 6:133-152
34. Lin S, Zhang G, Liao Y, Pan J, Gong D. Dietary Flavonoids as Xanthine Oxidase Inhibitors: Structure-Affinity and Structure-Activity Relationships. J Agric Food Chem. 2015; 63:7784-7794
35. Battelli MG, Bolognesi A, Polito L. Pathophysiology of circulating xanthine oxidoreductase: new emerging roles for a multi-tasking enzyme. Biochim Biophys Acta. 2014; 1842:1502-1517
36. Chen AY, Lu JM, Yao Q, Chen C. Entacapone is an Antioxidant More Potent than Vitamin C and Vitamin E for Scavenging of Hypochlorous Acid and Peroxynitrite, and the Inhibition of Oxidative Stress-Induced Cell Death. Med Sci Monit. 2016; 22:687-696
37. Kelley EE. A new paradigm for XOR-catalyzed reactive species generation in the endothelium. Pharmacol Rep. 2015; 67:669-674
38. Battelli MG, Polito L. Xanthine Oxidoreductase-Derived Reactive Species: Physiological and Pathological Effects. Oxid Med Cell Longev. 2016; 2016:3527579
39. Dao VT, Casas AI, Maghzal GJ, Seredenina T, Kaludercic N, Robledinos-Anton N, Di Lisa F, Stocker R, Ghezzi P, Jaquet V, Cuadrado A, Schmidt HH. Pharmacology and Clinical Drug Candidates in Redox Medicine. Antioxid Redox Signal. 2015; 23:1113-1129
40. Smith JA, Park S, Krause JS, Banik NL. Oxidative stress, DNA damage, and the telomeric complex as therapeutic targets in acute neurodegeneration. Neurochem Int. 2013; 62:764-775
41. Loperena R, Harrison DG. Oxidative Stress and Hypertensive Diseases. Med Clin North Am. 2017; 101:169-193
42. Bhatti JS, Bhatti GK, Reddy PH. Mitochondrial dysfunction and oxidative stress in metabolic disorders-A step towards mitochondria based therapeutic strategies. Biochim Biophys Acta. 2016; 1863:1066-1077
43. Kim J, Kim J, Bae JS. ROS homeostasis and metabolism: a critical liaison for cancer therapy. Exp Mol Med. 2016; 48:e269
44. Koskenkorva-Frank TS, Weiss G, Koppenol WH, Burckhardt S. The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: insights into the potential of various iron therapies to induce oxidative and nitrosative stress. Free Radic Biol Med. 2013; 65:1174-1194
45. Gao Z, Huang K, Yang X, Xu H. Free radical scavenging and antioxidant activities of flavonoids extracted from the radix of Scutellaria baicalensis Georgi. Biochim Biophys Acta. 1999; 1472:643-650
46. Lin HY, Shen SC, Lin CW, Yang LY, Chen YC. Baicalein inhibition of hydrogen peroxide-induced apoptosis via ROS-dependent heme oxygenase 1 gene expression. Biochim Biophys Acta. 2007; 1773:1073-1086
47. Luo C, Lian X, Hong L, Zou J, Li Z, Zhu Y, Huang T, Zhang Y, Hu Y, Yuan H, Wen T, Zhuang W, Cai B, et al. High Uric Acid Activates the ROS-AMPK Pathway, Impairs CD68 Expression and Inhibits OxLDL-Induced Foam-Cell Formation in a Human Monocytic Cell Line, THP-1. Cell Physiol Biochem. 2016; 40:538-548
48. Wang M, Zhao J, Zhang N, Chen J. Astilbin improves potassium oxonate-induced hyperuricemia and kidney injury through regulating oxidative stress and inflammation response in mice. Biomed Pharmacother. 2016; 83:975-988
49. Liu N, Wang L, Yang T, Xiong C, Xu L, Shi Y, Bao W, Chin YE, Cheng SB, Yan H, Qiu A, Zhuang S. EGF Receptor Inhibition Alleviates Hyperuricemic Nephropathy. J Am Soc Nephrol. 2015; 26:2716-2729
50. Canepa M, Viazzi F, Strait JB, Ameri P, Pontremoli R, Brunelli C, Studenski S, Ferrucci L, Lakatta EG, AlGhatrif M. Longitudinal Association Between Serum Uric Acid and Arterial Stiffness: Results From the Baltimore Longitudinal Study of Aging. Hypertension. 2016
51. Prasad M, Matteson EL, Herrmann J, Gulati R, Rihal CS, Lerman LO, Lerman A. Uric Acid Is Associated With Inflammation, Coronary Microvascular Dysfunction, and Adverse Outcomes in Postmenopausal Women. Hypertension. 2016; 69:228-235
52. Tan RJ, Liu Y. Matrix metalloproteinases in kidney homeostasis and diseases. Am J Physiol Renal Physiol. 2012; 302:F1351-1361
53. Zhou D, Tian Y, Sun L, Zhou L, Xiao L, Tan RJ, Tian J, Fu H, Hou FF, Liu Y. Matrix Metalloproteinase-7 Is a Urinary Biomarker and Pathogenic Mediator of Kidney Fibrosis. J Am Soc Nephrol. 2016; 28:598-611
54. Hopps E, Caimi G. Matrix metalloproteases as a pharmacological target in cardiovascular diseases. Eur Rev Med Pharmacol Sci. 2015; 19:2583-2589
55. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006; 69:562-573
56. Fu X, Kao JL, Bergt C, Kassim SY, Huq NP, d'Avignon A, Parks WC, Mecham RP, Heinecke JW. Oxidative cross-linking of tryptophan to glycine restrains matrix metalloproteinase activity: specific structural motifs control protein oxidation. J Biol Chem. 2004; 279:6209-6212
57. Kato H, Gruenwald A, Suh JH, Miner JH, Barisoni-Thomas L, Taketo MM, Faul C, Millar SE, Holzman LB, Susztak K. Wnt/beta-catenin pathway in podocytes integrates cell adhesion, differentiation, and survival. J Biol Chem. 2011; 286:26003-26015
58. Dai C, Stolz DB, Kiss LP, Monga SP, Holzman LB, Liu Y. Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria. J Am Soc Nephrol. 2009; 20:1997-2008
59. Kim H, He Y, Yang I, Zeng Y, Kim Y, Seo YW, Murnane MJ, Jung C, Lee JH, Min JJ, Kwon DD, Kim KK, Lu Q, et al. delta-Catenin promotes E-cadherin processing and activates beta-catenin-mediated signaling: implications on human prostate cancer progression. Biochim Biophys Acta. 2012; 1822:509-521
60. Padwal M, Siddique I, Wu L, Tang K, Boivin F, Liu L, Robertson J, Bridgewater D, West-Mays J, Gangji A, Brimble KS, Margetts PJ. Matrix metalloproteinase 9 is associated with peritoneal membrane solute transport and induces angiogenesis through beta-catenin signaling. Nephrol Dial Transplant. 2016; 32:50-61
61. He W, Tan RJ, Li Y, Wang D, Nie J, Hou FF, Liu Y. Matrix metalloproteinase-7 as a surrogate marker predicts renal Wnt/beta-catenin activity in CKD. J Am Soc Nephrol. 2012; 23:294-304
62. Zheng G, Lyons JG, Tan TK, Wang Y, Hsu TT, Min D, Succar L, Rangan GK, Hu M, Henderson BR, Alexander SI, Harris DC. Disruption of E-cadherin by matrix metalloproteinase directly mediates epithelial-mesenchymal transition downstream of transforming growth factorbeta1 in renal tubular epithelial cells. Am J Pathol. 2009; 175:580-591